Broncus Holding Corporation (HKG:2216) has successfully completed the first case of registered clinical trials for its targeted lung denervation radiofrequency ablation system. The trial, led by Professor Luo Fengming at the West China Hospital of Sichuan University, is a multi-center study aimed at evaluating the safety and effectiveness of Broncus' denervation ablation system in treating Chronic Obstructive Pulmonary Disease (COPD). With 26 centers across China participating, this trial has the potential to benefit COPD patients worldwide. The clinical procedure was performed by a team led by Professor Liu Dan from the Department of Respiratory and Critical Care Medicine at West China Hospital of Sichuan University.
COPD is a prevalent chronic respiratory disease that affects millions of people globally. As reported by Frost & Sullivan, there were approximately 219.2 million COPD patients worldwide in 2020.